Sugi Predict

Sugi Predict / Compounds / SCHEMBL18375758

SCHEMBL18375758

SCHEMBL18375758

O=Cc1cn(C2CCN(C(=O)OCc3ccccc3)CC2)nn1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.55
▸ NPC1 O15118 2/20 0.55
▸ RAB9A P51151 2/20 0.55
▸ CYP2C19 P33261 1/20 0.53
▸ GRIN2B Q13224 9/20 0.48
▸ CYP2D6 P10635 4/20 0.47
▸ CYP2C9 P11712 4/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47
▸ KDM5C P41229 1/20 0.46
▸ KDM2A Q9Y2K7 1/20 0.46
▸ KDM3A Q9Y4C1 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ CYP3A4 P08684 3/20 0.45
▸ JAK2 O60674 1/20 0.45
▸ JAK1 P23458 1/20 0.45
▸ TYK2 P29597 1/20 0.45
▸ JAK3 P52333 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19732305 0.84 SMN1; SMN2 (0.57) SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B
SCHEMBL18368416 0.83 SMN1; SMN2 (0.59) SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B
SCHEMBL18379297 0.83 SMN1; SMN2 (0.55) SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B
SCHEMBL19726578 0.82 SMN1; SMN2 (0.54) SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B
SCHEMBL19732433 0.82 SMN1; SMN2 (0.54) SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B
SCHEMBL21733294 0.81 ALDH1A1 (0.55) JAK2JAK1TYK2
SCHEMBL30216229 0.81 ALDH1A1 (0.55) JAK2JAK1TYK2
SCHEMBL28497447 0.79 SMN1; SMN2 (0.50) SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B
SCHEMBL18378757 0.78 SMN1; SMN2 (0.52) SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B
SCHEMBL22702107 0.78 SMN1; SMN2 (0.52) SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119143730-A COT modulators and methods of use thereof 吉利德科学公司 2024-12-17 — — CN disclosed
CN-114380799-B COT modulators and methods of use thereof 吉利德科学公司 2024-10-01 — — CN disclosed
CN-114380799-A COT modulators and methods of use thereof 吉利德科学公司 2022-04-22 — — CN disclosed
CN-109879859-B COT modulators and methods of use thereof 吉利德科学公司 2022-01-25 — — CN disclosed
CN-108026067-B 6-amino-quinoline-3-carbonitriles as COT modulators 吉利德科学公司 2021-01-12 — — CN disclosed
EP-3478674-B1 4,6-DIAMINOQUINAZOLINES AS COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES INC (US) 2020-05-13 — — EP disclosed
EP-3478674-B1 4,6-DIAMINOQUINAZOLINES AS COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES INC (US) 2020-05-13 — — EP disclosed
US-10577352-B2 Cot modulators and methods of use thereof GILEAD SCIENCES, INC. (US) 2020-03-03 — — US disclosed
US-10577352-B2 Cot modulators and methods of use thereof GILEAD SCIENCES, INC. (US) 2020-03-03 — — US disclosed
US-20190016705-A1 COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES, INC. 2019-01-17 — — US disclosed
US-10059695-B2 Cot modulators and methods of use thereof GILEAD SCIENCES, INC. (US) 2018-08-28 — — US disclosed
US-9878995-B2 Cot modulators and methods of use thereof GILEAD SCIENCES, INC. (US) 2018-01-30 — — US disclosed
US-20180002316-A1 COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES, INC. 2018-01-04 — — US disclosed
US-20180002316-A1 COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES, INC. 2018-01-04 — — US disclosed
US-20170362201-A1 COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES, INC. 2017-12-21 — — US disclosed
US-9815818-B2 Cot modulators and methods of use thereof GILEAD SCIENCES, INC. (US) 2017-11-14 — — US disclosed
US-20170152240-A1 COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES, INC. 2017-06-01 — — US disclosed
US-20170152240-A1 COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES, INC. 2017-06-01 — — US disclosed
WO-2017007694-A1 6-AMINO-QUINOLINE-3-CARBONITRILS AS COT MODULATORS GILEAD SCIENCES, INC. (US) 2017-01-12 — — WO disclosed
US-20170008873-A1 COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES, INC. 2017-01-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170362201-A1 COT MODULATORS AND METHODS OF USE THEREOF BRDT, THRB, HCCS SMN1; SMN2 4716/4885NPC1 4279/4885RAB9A 4028/4885
US-10577352-B2 Cot modulators and methods of use thereof BRDT, THRB, HCCS SMN1; SMN2 4716/4885NPC1 4279/4885RAB9A 4028/4885
US-20180002316-A1 COT MODULATORS AND METHODS OF USE THEREOF BRDT, THRB, HCCS SMN1; SMN2 4716/4885NPC1 4279/4885RAB9A 4028/4885
US-20190016705-A1 COT MODULATORS AND METHODS OF USE THEREOF BRDT, THRB, HCCS SMN1; SMN2 4716/4885NPC1 4279/4885RAB9A 4028/4885
US-20170152240-A1 COT MODULATORS AND METHODS OF USE THEREOF BRDT, THRB, HCCS SMN1; SMN2 4716/4885NPC1 4279/4885RAB9A 4028/4885
US-10059695-B2 Cot modulators and methods of use thereof BRDT, THRB, HCCS SMN1; SMN2 4716/4885NPC1 4279/4885RAB9A 4028/4885
US-20170008873-A1 COT MODULATORS AND METHODS OF USE THEREOF BRDT, THRB, HCCS SMN1; SMN2 4716/4885NPC1 4279/4885RAB9A 4028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.